Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478012 | 0.98 | RARB (0.49) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL8552636 | 0.98 | RARB (0.49) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL8126315 | 0.98 | RARB (0.49) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL7474682 | 0.98 | RARB (0.49) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL12760430 | 0.93 | NFKB1 (0.46) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL303902 | 0.84 | NPC1 (0.40) | L3MBTL1TDP1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6417146 | 0.80 | RARB (0.47) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL4563146 | 0.78 | RAB9A (0.50) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL7910575 | 0.78 | PTGS2 (0.52) | RARBL3MBTL1TDP1MAPTRAB9A | |
| SCHEMBL12186163 | 0.78 | RARB (0.50) | RARBL3MBTL1TDP1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879183-B2 | Liquid crystal compound having CF2O bonding group and tolan skeleton, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9879183-B2 | Liquid crystal compound having CF2O bonding group and tolan skeleton, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-2351741-B1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING NITROGEN-CONTAINING HETEROCYCLIC RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9187450-B2 | Substituted pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2592076-B1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-8993754-B2 | Iridium complex and light emitting material formed from same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20140213549-A9 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| EP-2471800-B1 | IRIDIUM COMPLEX AND LIGHT EMITTING MATERIAL FORMED FROM SAME | NAT INST OF ADVANCED IND SCIEN (JP) | 2014-01-15 | — | — | EP | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| US-6329027-B1 | Chlorobenzene derivatives, liquid-crystal composition, and liquid-crystal display elements | CHISSO CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6326065-B1 | HIGH VOLTAGE HOLDING RATIO, HIGH .DELTA.N AND HIGH .DELTA..EPSILON., EXCELLENT MISCIBILITY AT LOW TEMPERATURES; USED FOR THIN FILM TRANSISTORS | CHISSO CORPORATION (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1006109-A1 | Pyrimidine derivative, liquid crystal composition comprising the derivative, and liquid crystal display device fabricated by using the composition | CHISSO CORPORATION (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0959060-A1 | CHLOROBENZENE DERIVATIVES, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENTS | CHISSO CORPORATION (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5454975-A | Electrooptical display | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | RARB 521/4885L3MBTL1 4668/4885TDP1 4755/4885 |
| US-20140213549-A9 | Substituted Pyridine Compound | CETP, MTTP, PRCP | RARB 4441/4885L3MBTL1 3751/4885TDP1 1950/4885 |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, TLN1, TCOF1 | RARB 4443/4885L3MBTL1 2176/4885TDP1 883/4885 |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | CXCR4, CXCL12, CCR5 | RARB 1227/4885L3MBTL1 1359/4885TDP1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.